Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Jiashen Tablets in Healthy Subjects
NCT04164290Phase 1Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Jiashen Tablets in heart failure (HF) (15 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoints: Adverse Events, Abnormal Blood Pressure and 11 more. Started Jun 2020; status: completed.
02
Drugs
Jiashen Tablets
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04164290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164290.